Admitting Its Limitations, Bio-Rad Contends SELDI Still Valuable for Biomarker Discovery | GenomeWeb
In their most extensive public comments about the SELDI platform since Bio-Rad Laboratories acquired it from Ciphergen Biosystems last year, officials from Bio-Rad said that despite its shortcomings, the technology is still a valuable tool in the search for biomarkers.
Since purchasing the surface enhanced laser desorption ionization system from Ciphergen last November, Bio-Rad has stayed largely silent about the controversial technology and its plans for it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.